Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says

MT Newswires Live02:52

Scholar Rock (SRRK) could face some friction during the early commercialization of Isembyld after the drugmaker clarified that the US Food and Drug Administration has required a post-marketing pregnancy safety study and requested 15-day reports for serious and non-serious fracture cases, Truist Securities said in a note Tuesday.

The FDA recently approved Isembyld to treat spinal muscular atrophy in adults and children two years of age and older.

The fracture rate observed in the Isembyld trial appears consistent with historical rates in patients with spinal muscular atrophy, while management reported no change in bone mineral density in the Phase 2 EMBRACE study, Truist said.

The brokerage expects fracture reports to be reflected in periodic FDA Adverse Event Reporting System updates, as Scholar Rock does not expect to announce individual new fracture cases.

Truist continues to see potential for Isembyld to reach peak sales of $2.3 billion.

Truist maintained a buy rating with $76 price target.

Price: 47.83, Change: -4.02, Percent Change: -7.75

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment